Compare JPMorgan Chase & Co (JPM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs 10X Genomics Inc — how do they compare? JPMorgan Chase & Co trades at $342.49 (market cap $900.78B), while 10X Genomics Inc trades at $45.06 (market cap $5.48B). The key difference: JPMorgan Chase & Co is far larger — about 164.4× 10X Genomics Inc's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| JPM | TXG | |
|---|---|---|
Market Cap | $900.78B | $5.48B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $45.80 |
52-Week Low | $282.84 | $11.34 |
Dividend Yield | 1.77% | — |
Enterprise Value | — | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase trades at $339.90, down 0.35% on the day, with strong technical momentum showing bullish moving averages and key support at $339. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026, with revenue growing to $181.85 billion in 2025. Analyst consensus remains positive with a $372.73 price target, though CEO Jamie Dimon's recent warnings highlight economic risks.
JPMorgan presents a compelling investment case with solid fundamentals and Wall Street support, though investors face risks from macroeconomic volatility, cybersecurity threats, and geopolitical tensions. The stock's current valuation below analyst targets suggests potential upside if earnings momentum continues through upcoming quarterly results.
TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.
The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
